摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-azido-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylidene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one | 253128-40-4

中文名称
——
中文别名
——
英文名称
(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-azido-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylidene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.13,32.13,33.16,9.112,16.018,22.029,36.031,35]hentetracontan-24-one
英文别名
——
(1S,3S,6S,9S,12S,14R,16R,18S,20R,21R,22S,26R,29S,31R,32S,33R,35R,36S)-20-[(2S)-3-azido-2-hydroxypropyl]-21-methoxy-14-methyl-8,15-bis(methylidene)-2,19,30,34,37,39,40,41-octaoxanonacyclo[24.9.2.1<sup>3</sup><sup>,</sup><sup>32</sup>.1<sup>3</sup><sup>,</sup><sup>33</sup>.1<sup>6</sup><sup>,</sup><sup>9</sup>.1<sup>12</sup><sup>,</sup><sup>16</sup>.0<sup>18</sup><sup>,</sup><sup>22</sup>.0<sup>29</sup><sup>,</sup><sup>36</sup>.0<sup>31</sup><sup>,</sup><sup>35</sup>]hentetracontan-24-one化学式
CAS
253128-40-4
化学式
C40H57N3O11
mdl
——
分子量
755.906
InChiKey
OGBZCUMNJQZLQT-JBQZKEIOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.79
  • 重原子数:
    54.0
  • 可旋转键数:
    5.0
  • 环数:
    10.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    169.13
  • 氢给体数:
    1.0
  • 氢受体数:
    12.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Intermediate compounds for preparing macrocylcic analogs
    申请人:Eisai Co., Ltd.
    公开号:US06365759B1
    公开(公告)日:2002-04-02
    Intermediate compounds of the formulas for use in the preparation of macrocyclic analogs.
    用于制备大环类似物的中间化合物的化学式。
  • [EN] PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ÉRIBULINE ET DE SES INTERMÉDIAIRES
    申请人:DR REDDYS LABORATORIES LTD
    公开号:WO2020075027A1
    公开(公告)日:2020-04-16
    The present application relate to crystalline azide compound of formula (II) which is used as an intermediate for the preparation of halichondrin B analogues such as eribulin or pharmaceutically acceptable salts thereof. The present application also covers purification process of azide compound of formula (II) and its further conversion to eribulin or a pharmaceutically acceptable salts thereof.
    本申请涉及式(II)的晶体偶氮化合物,其用作制备半乳霉素B类似物如依利波胺或其药学上可接受的盐的中间体。本申请还涵盖式(II)的偶氮化合物的纯化过程及其进一步转化为依利波胺或其药学上可接受的盐的过程。
  • Macrocyclic ketone analogues of halichondrin B
    作者:Wanjun Zheng、Boris M. Seletsky、Monica H. Palme、Paul J. Lydon、Lori A. Singer、Charles E. Chase、Charles A. Lemelin、Yongchun Shen、Heather Davis、Lynda Tremblay、Murray J. Towle、Kathleen A. Salvato、Bruce F. Wels、Kimberley K. Aalfs、Yoshito Kishi、Bruce A. Littlefield、Melvin J. Yu
    DOI:10.1016/j.bmcl.2004.08.069
    日期:2004.11
    Structurally simplified macrocyclic ketone analogues of halichondrin B were prepared by total synthesis and found to retain the potent cell growth inhibitory activity in vitro, stability in mouse serum, and in vivo efficacy of the natural product. (C) 2004 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

马桑宁内酯 薁并[6,5-b]呋喃-2,4-二酮,十氢-5-(3-羟基丙氧基)-3a,4a-二甲基- 苦毒浆果[木防已属] 苦亭 艾瑞布林中间体 艾瑞布林 甲磺酸艾日布林 木防己苦毒宁 呋喃并[4,3,2-ij][2]苯并吡喃-2,7-二酮,2a,3,4,6,8a,8b-六氢-6-甲基-5-[(1S)-1,3,3-三甲基环己基]-,(2aR,6R,8aS,8bR)- 全内酯 二氢苦毒宁 6-甲基-4-氧代-4H-呋喃并[3,2-c]吡喃-3-甲酰氯 6-(4-羟基苯基)-2,3,3-三甲基-2H-呋喃并[5,4-b]吡喃-4-酮 4H-呋喃并[2,3-c]吡喃基莫匹罗星钠 3-甲基2H-呋喃并[2,3-c]吡喃-2-酮 3,5-二甲基2H-呋喃并[2,3-c]吡喃-2-酮 2H-呋喃并[2,3-c]吡喃-2-酮 2-[(1E,3E)-己-1,3-二烯基]-2,6-二甲基-5,6-二氢呋喃并[5,4-b]吡喃-3,4-二酮 (3aS,5S,6R,9E,14R,15R,15aR)-2,3,3a,4,5,6,7,8,11,12,13,14,15,15alpha-十四氢-6,10,14-三甲基-3-亚甲基-2-氧代-5,15-环氧环十四烷并[b]呋喃-6-醇乙酸酯 (3aR,4S,7aR)-4-羟基-3,3a,4,7a-四氢呋喃并[5,4-b]吡喃-2-酮 (3aα,3bβ,6aβ,7aα)-(+/-)-hexahydro-6-hydroxy-3a-(phenylmethyl)difuro<2,3-b:3',4'-d>furan-2(3H)-one (2R,3aS,4S,6S,7aR)-3a-benzyloxy-6-ethynyl-2-methoxy-4-p-methoxybenzyloxyhexahydrofuro[2,3-b]pyran (1R,2S,6S,7S)-5,6-Dimethoxy-8-oxo-3,9-dioxa-tricyclo[5.2.2.02,6]undeca-4,10-diene-10-carboxylic acid methyl ester N3,5'-Cyclo-2',3'-O-isopropyliden-8-oxyguanosin (3aR,4aR,7aS,8aS)-2-Thioxo-hexahydro-furo[3',4':4,5]benzo[1,2-d][1,3]dioxol-5-one 9-(3',5'-O-Isopropyliden-2-keto-β-D-xylofuranosyl)-adenin (1aR,1bS,4aS,5aS)-1a-Isopropyl-hexahydro-1,4-dioxa-cyclopropa[a]pentalen-3-one [(3aR,4S,6R,7S,7aR)-7-acetyloxy-2-oxo-4-phenylsulfanyl-3,3a,4,6,7,7a-hexahydropyrano[3,4-d][1,3]oxazol-6-yl]methyl acetate (2R,3R,3aS,6R,7R,7aR)-7-azido-6-methoxy-2-phenylsulfanyl-hexahydrofuro[3,2-b]pyran-3-ol 7-Dihydroxymethyl-O1,O2-isopropyliden-3,7-anhydro-6-desoxy-D-glucofuranose (1S,2S,6S,7R)-5,6-Dimethoxy-8-oxo-3,9-dioxa-tricyclo[5.2.2.02,6]undeca-4,10-diene-10-carboxylic acid methyl ester (2R,3S)-2-Methyl-4-oxo-oxetane-3-carboxylic acid (1R,5S)-6-methylene-3-oxo-bicyclo[3.2.1]oct-1-ylmethyl ester 3-C-(3,4,6-tri-O-acetyl-2-deoxy-2-tetrachlorophthalimido-β-D-glucopyranosyl)-1-propene (2R,4aR,5aS,8aS,9S,9aR)-5a-methoxy-7-oxo-2-phenyloctahydrofuro[2',3':5,6]pyrano[3,2-d][1,3]dioxin-9-yl acetate (4R,5E,7R,9S,10S,11E,14S)-9-((benzyloxy)methoxy)-4,10-bis((tert-butyldimethylsilyl)oxy)-7-(dimethoxymethyl)-14-(furan-3-yl)-6,12-dimethyloxacyclotetradeca-5,11-dien-2-one 3-Furan-3-yl-8-methyl-5-(4,5,6,7-tetrahydro-isobenzofuran-4-yl)-2,7-dioxa-bicyclo[3.2.1]octane methyl 2,3"-anhydro-4,6-O-benzylidene-3-C-[2,2-dihydroxyethyl]-α-D-glucopyranoside (3aR,5S,6S,7aR)-5-((R)-but-3-en-2-yl)-6-hydroxyhexahydro-2H-furo[3,2-b]pyran-2-one 7-(3-Furan-3-yl-8-methyl-2,7-dioxa-bicyclo[3.2.1]oct-5-yl)-1,3,4,5,6,7-hexahydro-isobenzofuran-1-ol